Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Comment by Enriqueon Dec 11, 2018 11:11am
111 Views
Post# 29097012

RE:RE:RE:Liberty Health Sciences Inc (CNSX:LHS) Response to Short-Sel

RE:RE:RE:Liberty Health Sciences Inc (CNSX:LHS) Response to Short-SelGoing onto the HVT bullboard will give you a totally different sentiment. Very very refreshing seeing an optimistic view on this company because as a value investor, this makes me drool.

Their production capacity is very underwhelming, which is why it doesn’t have a lot of traction. But as you said the amount of leverage and potential product lines they can build with Dream Water is nuts! They just need to be exposed in more brick-and-mortar retail outlets. Satipharm also looks impressive. They also have approx. $50 million in cash, which is almost as much as their current market cap.

I’m curious as to what price you got in at. For the most part, I’ve made poorly timed dollar cost averaging moves to this point, but am considering it again. The one thing is even people that bought in at 1.25-1.50 still have a positive sentiment towards it, which makes me hopeful. I still feel shorting and tax loss selling is harming growth at the moment.

If it drops back down to 0.35ish, I’ll for sure average it out (missed the boat last week being narrow-sighted by APHA and LHS). Still lots to learn about the overall market but I’m extremely eager to learn. For the record, I entered at 0.55.
Bullboard Posts